What is Delve Bio?
Delve Bio is positioned at the intersection of biotechnology and data science, focusing on the development and application of advanced metagenomic sequencing technologies. The company's core competency lies in its ability to analyze complex microbial communities, offering insights crucial for various applications within the medical and research fields. This enterprise-level funding signifies a strong market validation for Delve Bio's innovative approach to understanding and leveraging genomic data.
How much funding has Delve Bio raised?
Delve Bio has raised a total of $35M across 1 funding round:
Series A
$35M
Series A (2023): $35M with participation from Section 32, GV, and Xontogeny Venture Fund II
Key Investors in Delve Bio
Section 32
Section 32 is a venture capital firm focused on investing in cutting-edge technology, particularly in the life sciences and enterprise solutions sectors. They back visionary entrepreneurs and innovative startups aiming to drive technological advancement.
GV
GV, formerly Google Ventures, is a venture capital firm that invests across multiple stages and sectors, with a strong emphasis on enterprise solutions, life sciences, and frontier technology. They provide financial backing to promising startups globally.
What's next for Delve Bio?
With this substantial strategic investment, Delve Bio is poised for significant expansion and further development of its proprietary metagenomic sequencing platforms. The capital injection is expected to fuel advancements in research and development, enhance operational capabilities, and potentially broaden the company's market reach. This financing round, characterized as a major strategic investment, suggests a focus on scaling operations and solidifying its position as a leader in metagenomic sequencing technology.
See full Delve Bio company page
